BidaskClub upgraded shares of InVitae Corp (NASDAQ:NVTA) from a sell rating to a hold rating in a report issued on Thursday.

NVTA has been the topic of a number of other reports. ValuEngine lowered shares of InVitae Corp from a sell rating to a strong sell rating in a research report on Tuesday, May 23rd. Zacks Investment Research lowered shares of InVitae Corp from a hold rating to a sell rating in a research report on Tuesday, July 18th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $12.69.

Shares of InVitae Corp (NASDAQ:NVTA) traded up 1.87% during mid-day trading on Thursday, reaching $10.34. 649,330 shares of the company were exchanged. The stock’s market capitalization is $437.53 million. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88. The stock has a 50 day moving average price of $9.49 and a 200-day moving average price of $9.75.

InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. InVitae Corp had a negative net margin of 260.48% and a negative return on equity of 119.10%. The firm had revenue of $10.34 million for the quarter, compared to analyst estimates of $10.90 million. During the same period last year, the firm posted ($0.80) EPS. InVitae Corp’s quarterly revenue was up 161.1% on a year-over-year basis. Analysts predict that InVitae Corp will post ($2.39) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “InVitae Corp (NVTA) Upgraded by BidaskClub to Hold” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/06/invitae-corp-nvta-upgraded-by-bidaskclub-to-hold.html.

Institutional investors have recently bought and sold shares of the stock. Donald L. Hagan LLC purchased a new position in InVitae Corp during the first quarter worth $111,000. Renaissance Technologies LLC purchased a new position in InVitae Corp during the fourth quarter worth $879,000. HighTower Advisors LLC raised its position in InVitae Corp by 11.9% in the first quarter. HighTower Advisors LLC now owns 252,744 shares of the medical research company’s stock worth $2,792,000 after buying an additional 26,787 shares during the period. State Street Corp raised its position in InVitae Corp by 9.4% in the fourth quarter. State Street Corp now owns 338,514 shares of the medical research company’s stock worth $2,688,000 after buying an additional 29,017 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in InVitae Corp during the first quarter worth $302,000.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.